Search
Tuesday 9 June 2015
  • :
  • :
Latest Update

Pre-Market News Analysis on: Orbitz Worldwide, (NYSE:OWW), Dollar Tree, (NASDAQ:DLTR), Immunomedics, (NASDAQ:IMMU), Lifelock (NYSE:LOCK)

On Friday, Orbitz Worldwide, Inc. (NYSE:OWW)’s shares inclined 0.26% to $11.42.

Orbitz Worldwide, Inc. (OWW) declared that at its annual stockholders meeting recently in Chicago, stockholders approved the merger agreement providing for the acquisition of Orbitz Worldwide by Expedia, Inc. (EXPE). About 74 percent of the shares outstanding voted in favor of the transaction. More than 99 percent of the votes cast were in favor of the transaction.

Expedia, Inc. and Orbitz Worldwide declared their entry into the merger agreement on Feb. 12, 2015, whereby Expedia agreed to acquire all outstanding shares of Orbitz Worldwide at $12 per share. On March 25, the two companies declared that they had each received a request for additional information and documentary material (“second request”) from the U.S. Department of Justice (DOJ) as part of the agency’s regulatory review. The two companies continue to fully cooperate with the DOJ. The transaction also remains subject to additional customary closing conditions.

Orbitz Worldwide, Inc. operates as an online travel company worldwide. It uses technology that enables leisure and business travelers to research, plan, and book a range of travel products and services, counting hotels, flights, vacation packages, car rentals, rail tickets, cruises, travel insurance, destination, services and event tickets. It also provides various travel administration services; and private label travel solutions to a range of partners.

Dollar Tree, Inc. (NASDAQ:DLTR)’s shares dropped -1.51% to $77.64.

Dollar Tree, Inc. (DLTR) issued a press release announcing it had reached a definitive agreement to sell Sycamore Partners a divestiture package of 330 Family Dollar stores contingent on completion of Dollar Tree’s pending acquisition of Family Dollar Stores, Inc. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and is incorporated herein by this reference.

The information contained in this item is being furnished to the Securities and Exchange Commission. Such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information shall not be deemed incorporated by reference into any registration statement or other document filed following the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise at the fixed price of $1.00. The company’s stores provide consumable merchandise, which comprises candy and food, and health and beauty care products; and everyday consumables, such as paper and chemicals, and frozen and refrigerated food.

At the end of Friday’s trade, Immunomedics, Inc. (NASDAQ:IMMU)‘s shares surged 7.16% to $4.34.

Immunomedics, Inc. (IMMU) declared an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients formerly treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).

For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the startning of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing.

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.

Lifelock Inc (NYSE:LOCK), ended its Friday’s trading session with 6.46% gain, and closed at $16.48.

Lifelock Inc (LOCK) declared a partnership that will focus on educating victims of domestic violence about the associated risks of identity theft.

LifeLock will work with Sojourner Center to raise awareness of the potential risks that victims of domestic violence may face and offer tools to educate them on how to better assist protect themselves.

The partnership is part of LifeLock’s ongoing consumer education efforts, which comprise partnering with community groups to assist protect potential victims of identity theft by providing them with information and protection tools.

LifeLock, Inc. provides identity theft protection services for consumers; and consumer risk administration services for enterprises in the United States. It protects consumer subscribers through monitoring identity-related events, such as new account openings and credit-related applications; and enterprise customers through delivering on-demand identity risk, identity authentication, and credit information about consumers.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *